Biosimilar Disruption
The entry of biosimilars is reshaping the Eylea Market. Biosimilars offer cost-effective alternatives that appeal to cost-conscious healthcare systems, especially in emerging markets. Several biosimilars have received regulatory approval and are entering commercial distribution. While this promotes wider access, it also puts pressure on pricing and profit margins. Innovators are responding with new delivery formats, such as high-dose formulations requiring fewer injections, and expanding into new indications to retain market share.
4 Ansichten
